Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factor? (adalimumab) in a Crohn's disease patient: case report and literature review.
Autor(es): Cesarini Monica; Angelucci Erika; Foglietta Tiziana; Vernia Piero
Resumo: Anti-tumor necrosis factor alpha antibodies have been used with increasing frequency despite the number of reported adverse effects. Further new information is still emerging. Here we report the case of a 71-years-old patient affected by Crohn's disease and HCV-positive who developed Guillain-Barrè syndrome after four injections of fully human anti-tumor necrosis factor alpha antibodies (adalimumab). Indication for the treatment was severe clinical recurrence of Crohn's disease following intestinal resection. Guillain-Barrè syndrome was treated by intravenous immunoglobulins, and methylprednisolone and plasmapheresis were started with a progressive partial resolution of neurological symptoms. To date, Crohn's disease was maintained in clinical remission with low dose steroid therapy.
Imprenta: Journal of Crohn's & Colitis, v. 5, n. 6, p. 619-622, 2011
Identificador do objeto digital: 10.1016/j.crohns.2011.06.010
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Cytokines
Data de publicação: 2011
